Sanofi India Reports Q4 FY26 Financial Results; Net Profit at ₹1,026 Million

1 min read     Updated on 29 Apr 2026, 08:59 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Sanofi India Limited has reported its financial results for the quarter ended March 31, 2026, with total income from operations at ₹4,767 million and net profit after tax at ₹1,026 million. The company's basic and diluted earnings per share stood at ₹44.55 for the quarter. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on April 28, 2026. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and are available on the company's website and stock exchange platforms.

powered bylight_fuzz_icon
39022156

*this image is generated using AI for illustrative purposes only.

Sanofi India Limited has announced its financial results for the quarter ended March 31, 2026, reporting total income from operations of ₹4,767 million for the period. The company's net profit after tax stood at ₹1,026 million, while net profit before tax reached ₹1,379 million. The basic and diluted earnings per share for the quarter were recorded at ₹44.55 each, based on a face value of ₹10 per share.

Financial Performance Summary

The company's total comprehensive income for the quarter ended March 31, 2026, was ₹1,026 million. Equity share capital remained constant at ₹230 million across all reported periods. The reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year stood at ₹7,262 million for the year ended December 31, 2025.

Comparative Performance

When compared with the previous quarter ended December 31, 2025, Sanofi India showed improvement in several key metrics. Total income from operations increased from ₹4,226 million in Q3 FY26 to ₹4,767 million in Q4 FY26. Net profit after tax also rose from ₹617 million to ₹1,026 million during the same period. However, compared with the corresponding quarter of the previous year ended March 31, 2025, total income declined from ₹5,392 million, while net profit after tax decreased from ₹1,195 million.

Key Financial Metrics

Particulars Quarter ended 31.03.2026 (Unaudited) Quarter ended 31.12.2025 (Unaudited) Quarter ended 31.03.2025 (Unaudited) Year ended 31.12.2025 (Audited)
Total income from operations ₹4,767 ₹4,226 ₹5,392 ₹18,571
Net Profit before Tax ₹1,379 ₹830 ₹1,653 ₹4,720
Net Profit after Tax ₹1,026 ₹617 ₹1,195 ₹3,267
Total Comprehensive Income ₹1,026 ₹634 ₹1,195 ₹3,284
Basic EPS (₹) 44.55 26.79 51.89 141.85
Diluted EPS (₹) 44.55 26.79 51.89 141.85

The financial results for the quarter ended March 31, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on April 28, 2026. The results have been prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read together with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India.

Historical Stock Returns for Sanofi

1 Day5 Days1 Month6 Months1 Year5 Years
-0.99%-4.16%+7.65%-27.66%-43.36%-54.37%

What strategic initiatives will Sanofi India implement to reverse the declining quarterly revenue trend in FY27?

How might the company's reduced profitability impact its R&D investments and new drug pipeline development?

Will Sanofi India consider portfolio restructuring or market expansion to compensate for the revenue decline?

Sanofi India Limited Publishes 70th AGM Notice Following Regulatory Requirements

2 min read     Updated on 03 Apr 2026, 04:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Sanofi India Limited has published regulatory newspaper notices for its 70th Annual General Meeting scheduled for April 29, 2026. The virtual meeting will cover final dividend approval of ₹48 per share, multiple director appointments including new independent directors, and approval of significant related party transactions. Remote e-voting will be available from April 25-28, 2026.

powered bylight_fuzz_icon
36700715

*this image is generated using AI for illustrative purposes only.

Sanofi India Limited has announced its 70th Annual General Meeting (AGM) scheduled for Wednesday, April 29, 2026 at 3:30 PM IST. The meeting will be conducted through video conferencing and other audio-visual means facility, in compliance with regulatory guidelines.

Regulatory Compliance and Publication

The company has fulfilled its regulatory obligations by publishing newspaper advertisements in Business Standard (English) and Sakal (Marathi) on April 3, 2026. This publication was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as confirmed by Company Secretary Haresh Vala in the official communication to stock exchanges.

Meeting Agenda and Key Business Items

The AGM will address both ordinary and special business matters crucial to the company's operations. The ordinary business includes adoption of audited financial statements for the financial year ended December 31, 2025, dividend matters, and director re-appointments.

Dividend Proposals

Dividend Type: Amount per Share (₹)
Interim Dividend: 75
Final Dividend: 48
Share Face Value: 10

The company will seek confirmation of interim dividend payment of ₹75 per equity share and declaration of final dividend of ₹48 per equity share for the financial year ended December 31, 2025.

Director Appointments and Re-appointments

The meeting will address several key leadership changes:

Re-appointments:

  • Mr. Vaibhav Karandikar (DIN: 09049375) - retiring by rotation
  • Mr. Eric Mansion (DIN: 10654588) - retiring by rotation

New Appointments:

  • Ms. Sudipta Chakraborty (DIN: 07166912) as Director and Whole-time Director for three years from March 1, 2026 to February 28, 2029
  • Mrs. Rajani Kesari (DIN: 02384170) as Independent Director for five years from April 1, 2026 to March 31, 2031
  • Mr. Siraj Azmat Chaudhry (DIN: 00161853) as Independent Director for five years from April 1, 2026 to March 31, 2031

Material Related Party Transactions

The company seeks approval for significant related party transactions expected to exceed materiality thresholds:

Related Party: Transaction Value (₹ million) Nature
Sanofi-Aventis Singapore Pte. Limited: Up to 13,850 Purchase/sale of goods, APIs, business support services
Sanofi Healthcare India Private Limited: Up to 5,300 Purchase/sale of goods, toll manufacturing, product development services

These transactions represent 75.38% and 28.85% of the company's annual turnover respectively for the preceding financial year.

Cost Auditor Remuneration

Shareholders will ratify the appointment and remuneration of M/s. Kishore Bhatia & Associates as Cost Auditors for the financial year ending December 31, 2026, with remuneration of ₹4,60,000 plus applicable taxes and out-of-pocket expenses.

Meeting Participation Guidelines

The AGM will accommodate 1,000 members on a first-come, first-served basis through video conferencing. Remote e-voting will be available from Saturday, April 25, 2026 at 9:00 AM to Tuesday, April 28, 2026 at 5:00 PM. The cut-off date for determining voting eligibility is Wednesday, April 22, 2026.

E-voting Schedule: Timing
Commencement: Saturday, April 25, 2026 at 9:00 AM IST
End: Tuesday, April 28, 2026 at 5:00 PM IST
Cut-off Date: Wednesday, April 22, 2026

Members can access the complete notice and annual report through the company's website and stock exchange portals. The company has appointed Mr. Gaurav Sainani or Mr. Sunny Gogiya from M/s. SGGS and Associates as scrutinizers for the voting process.

Historical Stock Returns for Sanofi

1 Day5 Days1 Month6 Months1 Year5 Years
-0.99%-4.16%+7.65%-27.66%-43.36%-54.37%

How will the substantial related party transactions worth ₹19,150 million impact Sanofi India's operational independence and pricing flexibility?

What strategic initiatives might the new leadership team, including Ms. Sudipta Chakraborty as Whole-time Director, implement to drive growth in India's pharmaceutical market?

Could the high dividend payout of ₹123 per share signal reduced capital allocation for R&D investments or expansion plans in the coming fiscal year?

More News on Sanofi

1 Year Returns:-43.36%